{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:49:10Z","timestamp":1790254150537,"version":"4.1.0"},"reference-count":50,"publisher":"Wiley","issue":"6","license":[{"start":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T00:00:00Z","timestamp":1742169600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clinical Endocrinology"],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title><jats:p>Pheochromocytoma and paraganglioma (together PPGL) are tumours with a high degree of heritability. Genetic landscape is divided into three clusters, cluster 1 (Krebs\/pseudohypoxia signalling pathway), cluster 2 (kinase signalling pathway) and cluster 3 (Wnt signalling pathway). With increasing knowledge in the field of genetics, cluster\u2010specific tumour characteristics, biochemical phenotype and imaging signatures are established in commonly found genes. The association of <jats:italic>FGFR1<\/jats:italic> pathogenic mutations with PPGL have been recently described although its features are not yet well established. Here, we present four patients with PPGL who were found to have somatic <jats:italic>FGFR1<\/jats:italic> pathogenic mutations. We discuss their clinical presentations, biochemical phenotypes, imaging signatures and treatment options that will be relevant for practicing physicians in managing these patients effectively.<\/jats:p>","DOI":"10.1111\/cen.15212","type":"journal-article","created":{"date-parts":[[2025,3,17]],"date-time":"2025-03-17T07:25:01Z","timestamp":1742196301000},"page":"626-634","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Series of Patients With <i>FGFR1<\/i>\u2010Related Pheochromocytoma and Paraganglioma With a Focus on Biochemical, Imaging Signatures and Treatment Options"],"prefix":"10.1111","volume":"102","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5754-1233","authenticated-orcid":false,"given":"Sakshi","family":"Jhawar","sequence":"first","affiliation":[{"name":"National Institute of Diabetes and Digestive and Kidney Diseases National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abhishek","family":"Jha","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Talvacchio","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junne","family":"Kamihara","sequence":"additional","affiliation":[{"name":"Dana\u2010Farber\/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School Boston Massachusetts USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaydira","family":"Del Rivero","sequence":"additional","affiliation":[{"name":"National Cancer Institute National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karel","family":"Pacak","sequence":"additional","affiliation":[{"name":"Eunice Kennedy Shriver National Institute of Child Health and Human Development National Institutes of Health Bethesda Maryland USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,3,17]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2017.01.001"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1210\/er.2017-00062"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa020152"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2022.09.003"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14030594"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnab019"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2019.00053"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/cen.14594"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-019-04398-1"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0165"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.2967\/jnumed.120.259689"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-12-0160"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.2214\/AJR.21.26071"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2213-8587(23)00256-5"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2024.2405866"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.29740"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3212"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells7070076"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-3357"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/1541-7786.MCR-10-0168"},{"key":"e_1_2_8_22_1","doi-asserted-by":"publisher","DOI":"10.1038\/ng.2682"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1002\/gcc.2870070407"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0020351"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.3001451"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15260"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-15-1841"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2013-4375"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa502"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc2780"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00268-017-4320-0"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0000000000002438"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers11101505"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1055\/a-0715-1888"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02554-0"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3703"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgae252"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1210\/en.2019-00410"},{"key":"e_1_2_8_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11864-020-00787-z"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13122968"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2308849"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101204"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1817323"},{"key":"e_1_2_8_44_1","unstructured":"\u201cBalversa Home Page \u201d accessed June 17 2024 https:\/\/www.balversa.com\/."},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-0697"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30109-1"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2206834"},{"key":"e_1_2_8_48_1","unstructured":"\u201cPemigatinib Prescribing Information \u201d accessed June 18 2024 https:\/\/www.pemazyre.com\/pemazyre-prescribing-information."},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1397663"},{"key":"e_1_2_8_50_1","unstructured":"\u201cHelsinn to Withdraw NDA for Cholangiocarcinoma \u201d FDA accessed June 18 2024 https:\/\/www.fdanews.com\/articles\/209797-helsinn-to-withdraw-nda-for-cholangiocarcinoma."},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23031450"}],"container-title":["Clinical Endocrinology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/cen.15212","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:32:07Z","timestamp":1746189127000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/cen.15212"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,17]]},"references-count":50,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["10.1111\/cen.15212"],"URL":"https:\/\/doi.org\/10.1111\/cen.15212","archive":["Portico"],"relation":{},"ISSN":["0300-0664","1365-2265"],"issn-type":[{"value":"0300-0664","type":"print"},{"value":"1365-2265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,17]]},"assertion":[{"value":"2024-11-25","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-17","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}